Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor

KOJI IZUMI, YICHUN ZHENG, YI LI, JACQUELINE ZAENGL and HIROSHI MIYAMOTO

1Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA;
2Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, PR. China

Received May 3, 2012; Accepted June 25, 2012
DOI: 10.3892/ijo.2012.1593

Abstract. Androgen receptor (AR) signals have been suggested to contribute to bladder tumorigenesis and cancer progression. Activation of epidermal growth factor receptor (EGFR) also leads to stimulation of bladder tumor growth. However, crosstalk between AR and EGFR pathways in bladder cancer remains uncharacterized. We have recently shown that androgens activate the EGFR pathway in bladder cancer cells. The purpose of this study was to investigate the effects of EGF on AR activity in bladder cancer. EGF increased AR transcriptional activity by 1.2-, 1.9- and 2.0-fold in UMUC3, 5637-AR and J82-AR cell lines, respectively, over mock treatment and a specific EGFR inhibitor, PD168393, antagonized the EGF effect. Combined treatment of EGF and dihydrotestosterone (DHT) further induced AR transactivation while an AR antagonist, hydroxyflutamide (HF), abolished the effect of not only DHT but also EGF. In growth assays, EGF alone/DHT alone/EGF+DHT increased cell numbers by 16/12/19%, 6/14/18% and 30/12/38% in UMUC3-control-shRNA, 5637-AR and J82-AR, respectively, whereas the effects of EGF were marginal or less significant in UMUC3-AR-shRNA (8%) or AR-negative 5637-V (<1%) and J82-V (17%) cells. HF treatment at least partially counteracted the EGF effect on the growth of AR-positive cells. Western blotting demonstrated that EGF, especially in the presence of DHT, upregulated the expression of the p160 coactivator TIF2 and HF again blocked this stimulation. Co-immunoprecipitation revealed the association between AR and estrogen receptor (ER)-β or Src in UMUC3 cells and stronger associations with EGF treatment, implying the involvement of the AR/ER/Src complex in EGF-increased AR transactivation and cell growth. Current results, thus, suggest that EGF promotes bladder cancer cell proliferation via modulation of AR signals. Taken together with our previous findings, crosstalk between EGFR and AR pathways can play an important role in the progression of bladder cancer.

Introduction

Epidemiological and clinical evidence has indicated a substantially higher risk of urinary bladder cancer in males yet there is a tendency showing more aggressive behavior in tumors from female patients. Recent experimental data suggest that urothelial carcinoma, like prostate and breast cancers, is an endocrine-related neoplasm (reviewed in ref. 3). In particular, the androgen receptor (AR) and estrogen receptor (ER) signaling pathways have been shown to contribute to bladder tumorigenesis and cancer progression, which may explain some of the differences in male versus female bladder cancer.

Activation of the epidermal growth factor (EGF) receptor (EGFR) family is known to involve the growth and progression of a variety of malignancies. In bladder cancer, EGFR/ERBB2 is frequently overexpressed, which correlates with higher tumor grade/stage and poorer prognosis. Experimental evidence in bladder cancer has also suggested that the EGFR pathway plays a critical role in cell proliferation, apoptosis, differentiation, migration and angiogenesis. Consequently, the efficacy of targeted therapy directed at EGFR signals has been assessed in bladder cancer.

The crosstalk between nuclear hormone receptors and growth factors leads to activation of nuclear receptor-mediated transcription. Specifically, in prostate cancer cells, AR signals upregulate EGFR and ERBB2 gene expression, whereas activation of EGFR and ERBB2 modulates AR functions. It has also been shown that the assembly of the EGFR/AR/ER/Src signaling complex is crucial for proliferation of prostate and breast cancer cells triggered by androgens, estrogens and/or EGF. In contrast, the relationship between the AR and EGFR pathways in bladder cancer remains poorly understood. We have recently shown that AR activation results in upregula-
tion of EGFR and ERBB2 expression in bladder cancer cells, which may play an important role in androgen-mediated tumor progression (26). In the present study, we investigated whether EGF could alter AR activity in bladder cancer cells.

Materials and methods

Cell culture and chemicals. Human bladder cancer cell lines, UMUC3, 5637 and J82, obtained from the American Type Culture Collection (Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere of 5% CO2. Cells were cultured in phenol-red free medium supplemented with 5% charcoal-stripped FBS at least 18 h before experimental treatment. We obtained dihydrotestosterone (DHT) and EGF from Sigma (St. Louis, MO, USA); hydroxyflutamide (HF) from Schering (Kenilworth, NJ, USA); and PD168393 from Calbiochem (San Diego, CA, USA).

Stable cell lines with AR and AR-short hairpin RNA (shRNA). Cell lines stably expressing a full-length wild-type human AR (5637-AR and J82-AR) or vector only (5637-V and J82-V) were established, using a lentivirus vector (pWPI-AR or pWPI-control) with psPAX2 envelope and pMD2.G packaging plasmids, as we described previously (11,26). Similarly, stable AR knockdown/control cell lines (UMUC3-AR-shRNA/UMUC3-control-shRNA) were established with a retrovirus vector pMSCV/U6-AR-shRNA or pMSCV/U6-control-shRNA (5,26).

Reporter gene assay. Bladder cancer cells at a density of 50-60% confluence in 24-well plates were co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of pRL-TK-luc plasmid DNA, using GeneJuice transfection reagent (Novagen, Gibbstown, NJ, USA). Six hours after transfection, the medium was replaced with one supplemented with 5% charcoal-stripped FBS containing ethanol or ligands (DHT, HF, EGF and/or PD168393) for 24 h. Cells were harvested, lysed and assayed for luciferase activity determined using a dual-luciferase reporter assay kit (Promega, Madison, WI, USA) and luminometer (TD-20/20; Turner BioSystems, Sunnyvale, CA, USA).

Cell proliferation assay. We used the MTT (methyl thiazolyl diphenyl tetrazolium bromide) assay to assess cell viability, as described previously (26,27). Briefly, cells (3x10^4) seeded in 96-well tissue culture plates were incubated with medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF and EGF). The media were refreshed every 24 h. After 96 h of treatment, 10 µl MTT (Sigma) stock solution (5 mg/ml) was added to each well with 0.1 ml of medium for 4 h at 37°C. The medium was replaced with 100 µl DMSO followed by incubation for 5 min at room temperature. The absorbance was then measured at a wavelength of 570 nm with background subtraction at 655 nm.

Western blotting. Protein extraction and western blotting were performed, as described previously (27) with minor modifications. Briefly, equal amounts of protein (20 µg) obtained from cell extracts were separated in a 10% sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA) by electroblotting using a standard protocol. Specific antibody binding was detected, using an anti-AR antibody (clone N20; diluted 1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), an anti-transcriptional intermediary factor 2 (TIF2) antibody (clone 29/TIF2; diluted 1:1,000; BD Bioscience, Franklin Lakes, NJ, USA), or an anti-GAPDH antibody (clone 6C5; diluted 1:1,000; Santa Cruz Biotechnology), with horseradish peroxidase detection system (SuperSignal West Pico Chemiluminescent Substrate; Thermo Scientific, Rockford, IL, USA).

Co-immunoprecipitation. UMUC3 cells were treated with mock (ethanol) or EGF for 24 h and protein (500 µg) from the cell lysates was incubated with 2 µg of anti-AR antibody (N20) or normal rabbit IgG (Santa Cruz Biotechnology) for 1 h and washed thrice with radio-immunoprecipitation assay buffer. Then, the complex was resolved on a 10% SDS-PAGE, transferred to the membrane and blotted with an anti-ERβ antibody (clone 14C8; diluted 1:500; Abcam, Cambridge, MA, USA) or an anti-v-Src antibody (clone 327; diluted 1:1,000; Calbiochem).

Statistical analysis. Student's t-test was used to analyze differences in relative luciferase activity and relative cell number between the two groups. P<0.05 was considered statistically significant.

Results

EGF mediates AR transactivation via EGFR. Because previous studies showed ligand-independent activation of AR transcrip

Antiandrogen blocks EGF-induced AR transactivation. We next assessed the effect of EGF, in conjunction with androgen and/or antiandrogen, on AR transcriptional activity in bladder cancer cells. As shown in Fig. 2A, DHT treatment increased AR transcription by 25% (lanes 1 vs. 3, p=0.032) and addition of EGF further induced it by 35% (lanes 1 vs. 4, p=0.001; lanes 3 vs. 4, p=0.103) in UMUC3. Interestingly, HF showing
only marginal activity (lanes 1 vs. 5) abolished the effects of not only DHT (lanes 3 vs. 7, \( p=0.077 \)) but also EGF (lanes 2 vs. 6, \( p=0.061 \)) and EGF+DHT (lanes 4 vs. 8, \( p=0.082 \)). Similarly, in 5637-AR (Fig. 2B) and J82-AR (Fig. 2C), DHT (lane 3) induced AR transcription to 52- and 7.4-fold, respectively and EGF in the presence of DHT (lanes 4 vs. 3) enhanced it to 78- (\( p=0.035 \)) and 30-fold (\( p=0.054 \)), respectively. HF showing some agonist activities (lanes 1 vs. 5) in 5637-AR (15-fold)/J82-AR (1.8-fold), which were much higher (vs. 1.7-fold)/similar (vs. 2.1-fold) compared to EGF stimulations (lane 2), could block the effects of DHT (lanes 3 vs. 7, \( p=0.005/p=0.164 \)) and EGF+DHT (lanes 4 vs. 8, \( p=0.009/p=0.013 \)). Again, in UMUC3-AR-shRNA, 5637(-V) and J82(-V) cells, EGF, DHT and/or HF showed marginal effects on AR transcription (data not shown). These findings suggest that EGF and androgen cooperatively induce AR transactivation that is sufficiently inhibited by an anti-androgen.

**EGF stimulates cell growth via AR signaling.** We then performed the MTT assay to investigate the effects of EGF and antiandrogen on cell proliferation of bladder cancer lines with vs. without AR (i.e., UMUC3-control-shRNA vs. UMUC3-AR-shRNA, 5637-AR vs. 5637-V and J82-AR vs. J82-V). As shown in Fig. 3A, in UMUC3-control-shRNA, treatment of EGF, DHT and EGF+DHT increased cell growth by 16% (\( p=0.020 \)), 12% (\( p=0.195 \)) and 19% (\( p=0.009 \)), respectively, over mock treatment and HF treatment appeared to restore the growth to the basal levels. In UMUC3-AR-shRNA, DHT effect was marginal (2%) and the effects of EGF (8%, \( p=0.039 \)) and EGF+DHT (11%, \( p=0.040 \)) were less significant compared to those in UMUC3-control-shRNA. In 5637-AR, treatment of EGF, DHT and EGF+DHT induced cell growth by 6% (\( p=0.558 \)), 14% (\( p=0.016 \)) and 19% (\( p=0.050 \)), respectively and HF almost completely abolished the stimulation (Fig. 3B). In 5637-V, only marginal effects of EGF, DHT and/or HF on cell numbers were seen. In J82-AR, treatment of EGF, DHT and EGF+DHT induced cell growth by 30% (\( p=0.001 \)), 12% (\( p=0.179 \)) and 38% (\( p<0.001 \)), respectively (Fig. 3C). Interestingly, HF was able to antagonize the DHT effect but only partially blocked the EGF effect. As expected, in J82-V, DHT did not increase cell growth, while EGF and EGF+DHT, although less significant, induced it by 17% (\( p=0.010 \)) and 20% (\( p=0.043 \)), respectively. Additionally, HF failed to block the EGF effect in J82-V cells. These results suggest that EGF promotes bladder cancer cell proliferation at least partially through the AR pathway.

**EGF increases AR and TIF2 expression.** To further investigate how EGF influences AR signals, we examined AR expression by western blotting. In UMUC3, AR expression was increased by DHT (4.4-fold) and further enhanced by addition of EGF (6.4-fold), whereas no significant effect of EGF or HF was seen in the absence of DHT (Fig. 4A). HF clearly antagonized the effects of DHT with or without EGF. In J82-AR, EGF appeared to increase AR expression both in the presence (2.8-fold) and
absence (1.5-fold) of DHT and HF abolished these effects (Fig. 4C). In contrast, only marginal effects of EGF and/or DHT on AR expression were observed in 5637-AR (Fig. 4B).

Because EGF was shown to induce AR transcription by upregulating TIF2 expression in prostate cancer cells (21), we then determined the levels of TIF2 expression in bladder cancer cell lines upon treatment with EGF, androgen and/or androgen. As shown in middle panels of Fig. 4, EGF increased TIF2 expression in the presence (1.5- to 1.8-fold) and absence (1.2- to 1.3-fold) of DHT. DHT alone increased TIF2 expression only in 5637-AR (1.4-fold) and showed marginal effects in UMUC3 and J82-AR. In addition, HF abrogated EGF- and/or DHT-enhanced TIF2 expression in all these three lines.

**EGF induces AR association with ER and Src.** Previous studies in prostate and breast cancers demonstrated that EGF induced AR/ER/Src association, resulting in activation of Src signaling (25,28) and that Src signals phosphorylated tyrosine residue absence (1.5-fold) of DHT and HF abolished these effects (Fig. 4C). In contrast, only marginal effects of EGF and/or DHT on AR expression were observed in 5637-AR (Fig. 4B).

Because EGF was shown to induce AR transcription by upregulating TIF2 expression in prostate cancer cells (21), we then determined the levels of TIF2 expression in bladder cancer cell lines upon treatment with EGF, androgen and/or androgen. As shown in middle panels of Fig. 4, EGF increased TIF2 expression in the presence (1.5- to 1.8-fold) and absence (1.2- to 1.3-fold) of DHT. DHT alone increased TIF2 expression only in 5637-AR (1.4-fold) and showed marginal effects in UMUC3 and J82-AR. In addition, HF abrogated EGF- and/or DHT-enhanced TIF2 expression in all these three lines.

**EGF induces AR association with ER and Src.** Previous studies in prostate and breast cancers demonstrated that EGF induced AR/ER/Src association, resulting in activation of Src signaling (25,28) and that Src signals phosphorylated tyrosine residue absence (1.5-fold) of DHT and HF abolished these effects (Fig. 4C). In contrast, only marginal effects of EGF and/or DHT on AR expression were observed in 5637-AR (Fig. 4B).

Because EGF was shown to induce AR transcription by upregulating TIF2 expression in prostate cancer cells (21), we then determined the levels of TIF2 expression in bladder cancer cell lines upon treatment with EGF, androgen and/or androgen. As shown in middle panels of Fig. 4, EGF increased TIF2 expression in the presence (1.5- to 1.8-fold) and absence (1.2- to 1.3-fold) of DHT. DHT alone increased TIF2 expression only in 5637-AR (1.4-fold) and showed marginal effects in UMUC3 and J82-AR. In addition, HF abrogated EGF- and/or DHT-enhanced TIF2 expression in all these three lines.

**EGF induces AR association with ER and Src.** Previous studies in prostate and breast cancers demonstrated that EGF induced AR/ER/Src association, resulting in activation of Src signaling (25,28) and that Src signals phosphorylated tyrosine residue absence (1.5-fold) of DHT and HF abolished these effects (Fig. 4C). In contrast, only marginal effects of EGF and/or DHT on AR expression were observed in 5637-AR (Fig. 4B).

Because EGF was shown to induce AR transcription by upregulating TIF2 expression in prostate cancer cells (21), we then determined the levels of TIF2 expression in bladder cancer cell lines upon treatment with EGF, androgen and/or androgen. As shown in middle panels of Fig. 4, EGF increased TIF2 expression in the presence (1.5- to 1.8-fold) and absence (1.2- to 1.3-fold) of DHT. DHT alone increased TIF2 expression only in 5637-AR (1.4-fold) and showed marginal effects in UMUC3 and J82-AR. In addition, HF abrogated EGF- and/or DHT-enhanced TIF2 expression in all these three lines.
of AR, provoking its transactivation and cell proliferation (29). We therefore investigated whether EGF induced AR/ER/Src complex formation in UMUC3 which is ERβ-negative/ERα-positive (figure not shown). As shown in Fig. 5, both Src and ERβ were co-immunoprecipitated with AR in bladder cancer cells. Furthermore, EGF treatment facilitated the association of AR with ERβ or Src.

Discussion

Dysregulation of the EGFR family is well known to associate with bladder cancer (14-16). AR signals have also been implicated in bladder carcinogenesis and tumor progression (3,5,7,9-13). Nonetheless, crosstalk between the AR and EGFR pathways remains unclear in bladder cancer, although it has been widely studied in prostate cancer (20-24). We have recently shown that AR signals increase EGFR and ERBB2 expression and activity, suggesting androgen-mediated bladder cancer progression via the regulation of the EGFR/ERBB2 pathways (26). In the present study, we provided evidence suggesting that EGF could regulate cell proliferation by activating AR signals in bladder cancer.

In prostate cancer, accumulating evidence has indicated that EGFR/ERBB2 signals induce AR transactivation in an androgen-dependent and -independent manner (20-22). In bladder cancer cells, we here showed that EGF could activate AR transcription and PD168393, a specific inhibitor of EGFR, restored this EGF effect. These data suggest that EGF androgen-independently induces EGFR-activated ARE reporter activity in bladder cancer. However, it was shown that the effect of EGF on AR transcription might be almost negligible compared to the induction by androgens in prostate cancer (20,21). Similarly, in bladder cancer lines 5637-AR and J82-AR where a wild-type AR was stably overexpressed, the effect of EGF was less significant than that of DHT. On the other hand, in UMUC3 cells that possess endogenous AR, EGF effect (20% increase) is similar to the relatively insignificant effect of DHT (25% increase). In addition, PD168393 displayed agonist effects [1.5-fold (vs. 2.0-fold by EGF) or 7.4-fold by DHT)] on AR transcription in J82-AR via unknown mechanisms. It was described in prostate cancer cells that PD168393 upregulated AR target gene expression in the presence of androgen, possibly via blocking basal activity of EGFR or ERBB2 (30). Importantly, as shown in prostate cancer (21), a combination of EGF and androgen further induced AR transcriptional activity in all the three bladder cancer lines tested and the AR antagonist HF completely abolished AR transactivation induced by EGF, androgen, or both at least in UMUC3. We could not evaluate antagonistic effects of HF on EGF-induced AR transcription due to the considerable agonist activity of HF which was even higher than that of EGF in 5637-AR. Thus, our results support the possibility that EGF mediates AR transcriptional activity through the EGFR and AR pathways in bladder cancer cells.

Consistent with previous findings shown by others and us (5,7,9,26) androgens promoted AR-positive bladder cancer cell proliferation that was blocked by antiandrogens. These effects of androgens were suggested to be at least partially mediated through the EGFR pathway (26). In the present study, as expected, EGF increased the growth of AR-positive cells and, less significantly, that of AR-knockdown/negative cells. In AR-positive lines, combined treatment with EGF and androgen further induced cell proliferation. Of note were inhibitory effects of the AR antagonist on EGF- and EGF+androgen-increased cell growth. Specifically, on the growth of 5637-derived lines, EGF and/or DHT showed only marginal effects (5637-V) and HF almost completely abolished EGF-mediated effects (5637-AR). These findings indicate that EGF-induced cell proliferation involves the AR pathway in bladder cancer. Nonetheless, in J82-derived lines, EGF retained its effect on cell growth without AR (J82-V) and HF failed to completely inhibit EGF-increased cell proliferation (J82-AR), suggesting the involvement of those other than the AR pathway.

It has been reported that EGF is capable of inducing AR transactivation and protein expression in androgen-independent prostate cancer cells (21). Others also described negative regulation of AR expression and activity by EGFR signaling in prostate cancer (30,31). In bladder cancer cells, we previously showed increases in the expression of endogenous AR by androgen treatment (26), which was inconsistent with the results demonstrated by Boorjian et al (9). We also showed no significant increases in exogenously overexpressed AR (5637-AR) by DHT or in endogenous androgenic ARs by EGF (26). We confirmed our previous findings in the three lines tested and further showed EGF-enhanced AR overexpression in the presence of androgen in UMUC3 and J82-AR, but not in 5637-AR. The mechanism underlying this discrepancy in the response to the treatment of EGF+DHT between levels of exogenous AR expression in 5637 versus J82 remains uncertain. Repeatedly, the AR expression increased by androgen with or without EGF in bladder cancer cells was abolished by an AR antagonist.

EGF has been shown to enhance the expression or phosphorylation of TIF2, one of the p60 nuclear receptor coactivators, leading to an increase in AR transactivation in prostate cancer cells (21). Indeed, the expression of major AR coactivators, including TIF2, was detected in bladder cancer cell lines as well as in AR-positive and even AR-negative bladder tumor specimens and TIF2 knockdown resulted in a decrease in androgen-mediated cell proliferation (9). We here found that TIF2 was considerably (e.g., x1.5-fold) augmented in the presence of EGF and DHT in bladder cancer cells, while EGF or DHT alone could lead to marginal/only slight increases in TIF2 expression. Interestingly, like our results in AR expression/activity and cell proliferation, EGF-induced TIF2 upregulation was abolished by the antiandrogen. Although detailed mechanisms need to be clarified, these results may imply that elevated levels of TIF2 contribute to EGF/androgen-enhanced AR transactivation in bladder cancer cells.

In hormone-responsive cells expressing both AR and ER (α and/or β), such as prostate and breast cancers, AR/ER/Src association plays a crucial role in activation of Src signals trig-gered by EGF and/or sex hormones (25,28). It was noteworthy that either AR or ER antagonist sufficiently inhibited this EGF-mediated association and subsequent stimulatory effects (28). It has also been shown that Src mediates EGF-induced AR tyrosine phosphorylation in prostate cancer cells, which leads to an increase in AR transcriptional activity (29). Indeed, in many bladder cancer tissue specimens, AR and ER(α) were found to be co-expressed (3,10,12). In this study, we showed associations of AR with ERβ and Src in UMUC3 which were enhanced by EGF treatment. These findings suggest that EGF activates Src via assembling the AR/ER/Src complex, resulting
in AR transactivation and cell proliferation in bladder cancer. This may also justify the drastic inhibition of EGF-induced effects accomplished by antiandrogen treatment.

In conclusion, EGF could increase AR transcriptional activity and cell proliferation in bladder cancer. These EGF effects were likely mediated through the AR pathway involving upregulation of TIF2 expression as well as activation of Src signals due to forming an AR/ER/Src complex. These results, together with our previous findings, not only shed light on crosstalk between the AR and EGFR pathways in bladder cancer but also enhance the feasibility of androgen deprivation interfering with this crosstalk as a potential therapeutic approach.

Acknowledgements

H.M. was supported by the Department of Defense Prostate Cancer Research Program (W81XWH-09-1-0305).

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Scossaev E, Noyes K, Feng C and Messing E: Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115: 68-74, 2009.
3. Miyamoto H, Zheng Y and Izumi K: Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Targets 12: 14-22, 2012.
4. Shen SS, Smith CL, Hsieh J-T, et al: Expression of estrogen receptors-α and -β in bladder cancer cell lines and human bladder tumor tissue. Cancer 106: 2610-2616, 2006.
5. Miyamoto H, Yang Z, Chen Y-T, et al: Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99: 558-568, 2007.
6. Songpadve G, Okuno N, Weiss H, et al: Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 69: 1221-1226, 2007.
7. Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM and Reeder JE: Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol 8: 7, 2008.
8. Teng J, Wang Z-Y, Jarrard DF and Borljen DE: Roles of estrogen receptor α and β in modulating urothelial cell proliferation. Endocrinol Cancer 15: 351-364, 2008.
9. Boorjian SA, Heemers HV, Frank I, Farmer SA, Schmidt LJ, Sebo TJ and Tindall DJ: Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer 16: 123-137, 2009.
10. Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M and Sertcelik A: Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 29: 43-51, 2011.
11. Izumi K, Zheng Y, Hsu J-W, Chang C and Miyamoto H: Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinogen: Nov 15, 2011 (Epub ahead of print) doi: 10.1002/mc.21833.
12. Miyamoto H, Yao JL, Chaux A, et al: Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 109: 1716-1726, 2012.
13. Li Y, Izumi K and Miyamoto H: The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 42: 569-577, 2012.
14. Neal DE, Sharpeles L, Smith K, Fennelly J, Hall RR and Harris AL: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625, 1990.
15. Miyamoto H, Kubota Y, Noguchi S, et al: c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55: 679-683, 2000.
16. Latif F: HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 40: 56-63, 2004.
17. Bellmunt J, Hussain M and Dinney CP: Novel approaches with targeted therapies in bladder cancer. Crit Rev Oncol Hematol 46: 85-104, 2003.
18. Black PC, Agarwal PK and Dinney CPN: Targeted therapies in bladder cancer - an update. Urol Oncol 25: 433-438, 2007.
19. MacLaine NJ, Wood MD, Holder JC, Rees RW and Southgate J: Sensitivity of normal, paramalignant and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res 6: 53-63, 2008.
20. Culin Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 54: 5474-5478, 1994.
21. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS and Wilson EM: Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279: 7119-7130, 2004.
22. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J and Sawyers CL: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527, 2004.
23. Mukherjee B and Mayer D: Dihydrotestosterone interacts with EGFR/ERK signaling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Int J Oncol 33: 623-629, 2008.
24. Pignnon J-C, Koopmansch B, Nolens G, Delacroix L, W altar لدينغ و وينكلر R: Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res 69: 2941-2949, 2009.
25. Migliaccio A, Castoria G, Giovannielli MP and Auricchio F: Cross talk between epidermal growth factor (EGF) receptor and extra nuclear steroid receptors in cell lines. Mol Cell Endocrinol 327: 19-24, 2010.
26. Zheng Y, Izumi K, Yao JL and Miyamoto H: Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer 18: 451-464, 2011.
27. Canacci AM, Izumi K, Zheng Y, Gordetsky J, Yao JL and Miyamoto H: Expression of semenogelins I and II and its prognostic significance in human prostate cancer. Prostate 71: 1108-1114, 2011.
28. Migliaccio A, Di Domenico M, Castoria G, et al: Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65: 10585-10593, 2005.
29. Guo Z, Dai B, Jiang T, et al: Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10: 309-319, 2006.
30. Cai C, Portnoy DC, Wang H, Jiang X, Chen S and Balk SP: Promotion of bladder cancer growth in a transgenic mouse model of bladder cancer. J Natl Cancer Inst 94: 1051-1058, 1993.